Christopher Lowe,
Professor,
University of Cambridge, Director, Cambridge Academy of Therapeutic Sciences
Professor Christopher R. Lowe was founder Director of the Institute of Biotechnology at the University of Cambridge and conducts research in both diagnostics and therapeutics in the healthcare biotechnology sector. He is a fellow of the Royal Academy of Engineering, the Institute of Physics and the Royal Society of Chemistry. He has 395 peer-reviewed publications, 8 books and monographs, >100 patents and has supervised >95 PhD students and has a number of national and international prizes: “Queen’s Award for Technological Achievement”; “Queen’s Anniversary Prize for Higher and Further Education”; “Most Entrepreneurial Scientist of the UK”; OBE in the Queen’s New Year Honours; BBSRC Commercial Innovator of the Year in 2011. He has been the driving force for the establishment of 11 spin-out companies including ProMetic Biosciences Inc (Market Cap $1.9-2.1B), Cambridge Sensors Ltd, Paramata Ltd, Psynova Neurotech Ltd and Royale Therapeutics Ltd., has a number of directorships and fosters entrepreneurship within the University via a Master’s in Bioscience Enterprise, the University’s Seed Fund Committee and other Business School and student-led activities. He is active in various government committees and in a number of legal and entrepreneurial roles. His group's primary research interest is in healthcare biotechnology, particularly where it is applied to the biopharmaceutical, sensors and diagnostics and enzyme and microbial technology sectors. The work is highly multidisciplinary and not only covers aspects of molecular biology, biochemistry, microbiology, chemistry, physics, electronics and engineering, but also the entire range from fundamental science to strategic and applied science. He is currently Director of the newly established Cambridge Academy of Therapeutic Sciences (CATS) within the University of Cambridge.
Many extravagant claims have been made in the past two decades about the likely impact of biosensors on the diagnostics industry: In reality, the current market size for biosensors represents ~14% of the global diagnostics market and is dominated entirely by sensors for one analyte, glucose. This presentation looks at the need for, and advantages of biosensors, the technology that has been developed over the past two decades to address these perceived needs, but, in reality, has failed to do so, and describes newer technologies which may circumvent the problems and suggests how they are likely to have a much more significant impact in the future, particularly in sectors such as medical diagnostics and biodetection. Examples of optical and acoustic technologies will be given.
Add to Calendar ▼2011-06-30 00:00:002011-07-01 00:00:00Europe/LondonEuropean Lab AutomationEuropean Lab Automation in HamburgHamburgSELECTBIOenquiries@selectbiosciences.com